Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More
Zacks Investment Research | Dec 03, 2019 10:02PM ET
It has been a pretty uneventful week for the biotech sector with updates from a few companies. While Incyte (NASDAQ:INCY) got Priority Review for the cholangiocarcinoma drug, Biogen (NASDAQ:BIIB) came out with positive results on the lupus drug. Meanwhile, Seattle Genetics (NASDAQ:SGEN) collaborated with Merck (NYSE:MRK) for a combination study.
Recap of the Week’s Most Important Stories:
Incyte's Pemigatinib Gets Priority Review: Incyte the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Biogen Announces Positive Lupus Drug Data: Biogen Inc. (BIIB) announced positive top-line results from the phase II LILAC study, which evaluated the efficacy and safety of pipeline candidate BIIB059 in lupus patients. BIIB059 is a fully-humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), currently being investigated for the treatment of active cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). The study met its primary endpoints, demonstrating a statistically significant reduction of disease activity in patients with CLE and SLE, who received BIIB059 compared to placebo.
Seattle Genetics & Astellas Join Merck for Cancer Study: Seattle Genetics along with Japanese partner Astellas Pharma, Inc inked a collaboration agreement with pharma giant Merck. Per the deal, the companies will begin a registrational phase III study for evaluating the combination of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin and Merck’s PD-1/L1 inhibitor Keytruda (pembrolizumab) to address patients with previously untreated metastatic urothelial cancer. The study, which will be led by Seattle Genetics, is expected to being in the first half of 2020. It is likely to support global registrations of enfortumab vedotin.
Cara Down on Study Results: Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) declined after the company announced top-line results from its phase II dose-ranging study of oral Korsuva (CR845/difelikefalin) for the treatment of pruritus in patients with stage III-V (moderate-to-severe) chronic kidney disease (CKD). The study met its primary endpoint with a statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength versus placebo after a 12-week treatment period. However, the study did not meet the secondary endpoints as the proportion of patients on 1 mg tablet strength achieving a 3-point or greater improvement from baseline in the weekly mean of the daily WI-NRS score at week 12 was 72% versus 58% for placebo but did not achieve statistical significance.
Axsome Gains on Positive Phase II Results: Shares of clinical-stage biopharmaceutical company, Axsome Therapeutics (NASDAQ:AXSM) , gained after it announced positive results from a mid-stage study on pipeline candidate, AXS-12 (reboxetine). The candidate met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT phase II study. AXS-12 also significantly reduced excessive daytime sleepiness (EDS), and improved cognitive function, sleep quality and sleep-related symptoms. AXS-12 has been granted Orphan Drug designation in the United States.
Performance
Get The News You Want
Medical - Biomedical and Genetics Industry 5YR % Return
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.